Once-Daily Abacavir in Place of Twice-Daily Administration

Abstract

Spanish

French

OBJECTIVE

To review the safety and efficacy of a once-daily dosage regimen for abacavir, a nucleoside reverse transcriptase inhibitor.

DATA SOURCES

English-language MEDLINE and Iowa Drug Information Service database reports were accessed from 1966 to March 2005. International Pharmaceutical Abstracts was searched from 1970 to March 2005. The key words used in all searches were abacavir and Ziagen. Article bibliographies were used to identify additional relevant articles. The Internet was searched to identify abstracts of poster and oral presentations that have not yet been published. The manufacturer was also contacted to obtain unpublished information.

STUDY SELECTION AND DATA EXTRACTION

Publications were included that provided information related to the safety and efficacy of abacavir when used once daily. Preference was given to randomized, double-blind, controlled trials comparing once-daily abacavir regimens with other antiretroviral regimens. Abstracts from professional meetings were included for unpublished studies, and conference coverage reviews were included if the abstracts were not available.

DATA SYNTHESIS

In trials directly comparing once- and twice-daily abacavir, little difference was shown in the efficacy of the 2 regimens. Despite similar adverse effect profiles, significantly more severe hypersensitivity reactions and severe diarrhea were seen with once-daily abacavir in one trial.

CONCLUSIONS

Once-daily administration of abacavir has not been shown to be inferior to twice-daily dosing, but it may put patients at increased risk for severe hypersensitivity reactions and diarrhea. More data are needed to confirm this risk.

Keywords

abacavir nucleoside reverse transcriptase inhibitor: dosing

Get full access to this article

View all access options for this article.

References

1. Ziagen label information. Drugs@FDA, Center for Drug Evaluation and Research. www.fda.gov/cder/foi/label/2004/20977s012,20978s014lbl.pdf (accessed 2005 May 23).

2. Katz

, Hollander

. Infectious diseases: HIV. Current medical diagnosis and treatment. www.accessmedicine.com/content.aspx?aID=23830 (accessed 2005 May 23).

3. Panel on Clinical Practices for Treatment of HIV Infection: guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. AIDSinfo, Department of Health & Human Services. www.aidsinfo.nih.gov/guidelines/adult/AA_040705.pdf (accessed 2005 May 23).

4. Cohen

. HIV lessons learned: the perils of extrapolation: combination NRTI use. Northwestern University Feinberg School of Medicine. clinicaloptions.com/assets/module/hivlessons/mar04/llmar04.pdf (accessed 2005 May 23).

5. Frank

. Once-daily HAART: toward a new treatment paradigm. J Acquir Immune Defic Syndr 2002; 31 (suppl 1): S10–5.

6. Birnkrant

. Ziagen new dosage regimen letter. Drugs@FDA, Center for Drug Evaluation and Research. www.fda.gov/cder/foi/appletter/2004/20977s012,20978s014ltr.pdf (accessed 2005 May 23).

7. Birnkrant

. Epzicom approval letter. Drugs@FDA, Center for Drug Evaluation and Research. www.fda.gov/cder/foi/appletter/2004/21652ltr.pdf (accessed 2005 May 23).

8. McDowell

, Chittick

, Ravitch

, Polk

. Pharmacokinetics of [14C] abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study. Antimicrob Agents Chemother 1999; 43: 2855–61.

9. Piliero

, Shachoy-Clark

, Para

, Preston

, Lou

, Drusano

, A study examining the pharmacokinetics of abacavir and the intracellular carbovir triphosphate (GSK protocol CNA10905) (abstract A-1797). Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 16, 2003.

10.

10. Piliero

. Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2004; 37 (Suppl 1): S2–12.

11.

11. Hawkins

, Veikley

, St. Claire

, Hey

, Guyer

, Kearney

. Intracellular pharmacokinetics of tenofovir-DP and carbovir-TP in patients receiving triple nucleoside regimens (abstract 6). Presented at: 5th International Workshop on Clinical Pharmacology of HIV Therapy, Rome, April 3, 2004.

12.

12. Bergshoeff

, Burger

, Farrelly

, Flynn

, LeProvost

, Novelli

, Pharmacokinetics of once daily vs twice daily lamivudine and abacavir in HIV-1–infected children: PENTA 13 (abstract 934). Presented at: 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 8, 2004.

13.

13. Gazzard

, DeJesus

, Cahn

, Castillo

, Zhao

, Gordon

, Abacavir (ABC) once daily (OAD) plus lamivudine (3TC) OAD in combination with efavirenz (EFV) OAD is well-tolerated and effective in the treatment of antiretroviral therapy (ART) naïve adults with HIV-1 infection (ZODIAC study: CNA30021) (oral presentation H-1722b). Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 16, 2003.

14.

14. Patel

. Data on file. Once daily administration of Ziagen. Research Triangle Park, NC: GlaxoSmithKline, 2004.

15.

15. Craig

, Stone

, Bonny

, Zhao

, Gordon

, Castillo

, Analysis of virologic failure in a clinical trial of abacavir once daily versus twice daily with lamivudine and efavirenz (abstract 551). Presented at: 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February 9, 2004.

16.

16. Moyle

, DeJesus

, Cahn

, Castillo

, Zhao

, Gordon

, Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naïve HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination study. J Acquir Immune Defic Syndr 2005; 38: 417–25.

17.

17. Gordon

, Hernandez

, Cutrell

, Zhao

, Bonny

, Castillo

, Long-term (>48 week) safety of abacavir (ABC) once daily (OAD) or twice daily (BID), in combination with lamivudine (3TC) OAD or BID and efavirenz (EFV) OAD (abstract WePeB5868). Presented at: XV International AIDS Conference, Bangkok, Thailand, July 14, 2004.

18.

18. Hernandez

, Gordon

, Cutrell

, Zhao

, Castillo

, Brothers

, Abacavir (ABC) has a similar safety profile when administered once daily (OAD) or twice daily (BID) in combination with lamivudine (3TC) and efavirenz (EFV) once daily to antiretroviral therapy (ART)-naïve, HIV-infected adults (abstract TuPeB4521). Presented at: XV International AIDS Conference, Bangkok, Thailand, July 13, 2004.

19.

19. James

, Johann-Liang

. Increased rate and severity of abacavir (ABC) associated hypersensitivity reaction (HSR) in prospective clinical trials (poster 835).ncreased rate and severity of abacavir (ABC) associated hypersensitivity reaction (HSR) in prospective clinical trials (poster 835). Presented at: 12th Conference on Retroviruses and Opportunistic Infections, Boston, February 23, 2005.

20.

20. Hill-Zabala

, Sosa

, DeJesus

, Herrera

, Florance

, Johnson

, Abacavir + lamivudine (ABC/3TC) fixed dose combination (FDC) once daily (QD) compared to ABC + 3TC twice daily (BID) in HIV-1 infected subjects (ESS30008) (poster P45). Presented at: Seventh International Congress on Drug Therapy in HIV Infection, Glasgow, UK, November 15, 2004.

21.

21. Watson

, Hill-Zabala

, Sosa

, DeJesus

, Florance

. Patient satisfaction with abacavir (ABC)–lamivudine (3TC) fixed dose combination (FDC) tablet once daily (QD) compared with ABC and 3TC twice daily (BID) in HIV-1 infected patients (ESS30008) (poster P44).atient satisfaction with abacavir (ABC)–lamivudine (3TC) fixed dose combination (FDC) tablet once daily (QD) compared with ABC and 3TC twice daily (BID) in HIV-1 infected patients (ESS30008) (poster P44). Presented at: Seventh International Congress on Drug Therapy in HIV Infection, Glasgow, UK, November 15, 2004.

22.

22. Sosa

, DeJesus

, Hill-Zabala

, Herrera

, Florance

, Vavro

, Abacavir + lamivudine (ABC/3TC) fixed dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-1 infected subjects over 48 weeks (ESS30008, SEAL) (poster 572). Presented at: 12th Conference on Retroviruses and Opportunistic Infections, Boston, February 25, 2005.

23.

23. Bowonwatanuwong

, Mootsikapun

, Supparatpinyo

, Tansuphaswadikul

, Athisegran

, Pasook

, A randomised, open label study to investigate abacavir (ABC) and lamivudine (3TC) as once daily (QD) components of a triple combination regimen (EPV40001) (abstract 4). Presented at: 1st International AIDS Society Conference on Pathogenesis and Treatment, Buenos Aires, Argentina, July 9, 2001.

24.

24. Clumeck

, Lamarca

, Fu

, Gordon

, Craig

, Zhao

, Safety and efficacy of a once daily (OAD) fixed-dose combination (FDC) of ABC/3TC [FDC arm] versus ABC twice daily (BID) and 3TC OAD as separate entities [SE arm] in ART-experienced HIV-1 infected patients (abstract H-558). Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October 30, 2004.

25.

25. Craig

, Stone

, Bonny

, Fu

. Similar virology findings in ABC/3TC fixed dose combination (FDC) OAD compared with standard dosing after 24 weeks in ART-experienced subjects (CAL30001, ALTO) (poster P314).imilar virology findings in ABC/3TC fixed dose combination (FDC) OAD compared with standard dosing after 24 weeks in ART-experienced subjects (CAL30001, ALTO) (poster P314). Presented at: Seventh International Congress on Drug Therapy in HIV Infection, Glasgow, UK, November 17, 2004.

26.

26. Ruane

, Lang

, DeJesus

, Berger

, Dretler

, Rodriguez

, Pilot study of once-daily (QD) quad therapy with Trizivir (ABC/3TC/ZDV) and efavirenz (EFV) (poster P46). Presented at: Seventh International Congress on Drug Therapy in HIV Infection, Glasgow, UK, November 15, 2004.

27.

27. Brothers

, Cutrell

, Zhao

, Edwards

, Fleming

, Scott

, Once daily administration of abacavir is not a clinical risk factor for suspected hypersensitivity reactions in clinical trials and rash alone is not sufficient to diagnose the reaction (poster 836). Presented at: 12th Conference on Retroviruses and Opportunistic Infections, Boston, February 23, 2005.